Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color

Journal of Drugs in Dermatology

Volumn 10, Issue 5, 2011, Pages 507-510

  Silverberg, Jonathan I ^a   Silverberg, Nanette B ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL FEATURE; DEPIGMENTATION; DRUG EFFICACY; FEMALE; HEAD AND NECK DISEASE; HUMAN; HYPOPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; SCHOOL CHILD; SKIN COLOR; TREATMENT RESPONSE; VITILIGO; ADULT; DOSE RESPONSE; FOLLOW UP; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; OINTMENT; PATHOLOGY; RACE; RETROSPECTIVE STUDY; SKIN PIGMENTATION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; RETROSPECTIVE STUDIES; SKIN PIGMENTATION; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VITILIGO; YOUNG ADULT;

EID: 80051629668     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010;22:445-452.
2. Shah S AA, Silverberg N. Treatment of Vitiligo in Children of Color. Asian Pigment Bulletin. January 2007.
3. Grimes PE. New insights and new therapies in vitiligo. JAMA. 2005;293:730-735. (Pubitemid 40216043)
4. Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: Children with head and neck involvement respond well. J Am Acad Dermatol. 2002;46:964-965.
5. Hadi SM, Spencer JM, Lebwohl M. The use of the 308-nm excimer laser for the treatment of vitiligo. Dermatol Surg. 2004;30:983-986. (Pubitemid 38890905)
6. Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274-278. (Pubitemid 46074252)
7. Hossani-Madani AR, Halder RM. Topical treatment and combination approaches for vitiligo: New insights, new developments. G Ital Dermatol Venereol. 2010;145:57-78.
8. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004;29:589-592. (Pubitemid 39573641)
9. Lo YH, Cheng GS, Huang CC, Chang WY, Wu CS. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. J Dermatol. 2010;37:125-129.
10. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051-1076.
11. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol. 2001;44(suppl 1):28-38.
12. Silverberg J, Silverberg A, Malka E, Silverberg N. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62:937-941.
13. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356:1216-1225. (Pubitemid 46465597)
14. Jin Y, Birlea SA, Fain PR, et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet. 2010;42:576-578.
15. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362:1686-1697.